11/7/2016 9:57:47 AM
Cologne, Germany, November 07, 2016 / B3C newswire / -- The supervisory board of AYOXXA Biosystems GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company as its orientation shifts toward market development and product refinement. The supervisory board and the management team wish to thank Dr. Andreas Schmidt for his years of leadership in founding and establishing AYOXXA as a leading biotech start-up in Germany. Dr. Schmidt has stepped down from his position as CEO, though he will remain associated with the company. Mr. Turner and Dr. Markus Zumbansen (CTO) were formally registered as managing directors of the company effective October 15, 2016.
Rodney Turner has been an independent member of the AYOXXA supervisory board since July 2014. Prior to March 2014, he was a senior corporate development executive with Life Technologies for almost 10 years, and has had a successful career as a senior business development executive at a number of biotech start-ups in the US and in Germany over the past 20 years.
“AYOXXA has come a long way in establishing a robust technical platform thanks to the excellent team in place at the company. I am eager to help the company focus on bringing its strong value proposition in protein analysis to basic and clinical researchers around the world,” said Rodney Turner.
Dr. Gerald Möller, Chairman of the AYOXXA Supervisory Board commented: “Andreas had done an excellent job in guiding the development of the AYOXXA technology and the growth of the company. As we look to the next phase of growth for AYOXXA we are fortunate to be able to draw upon Rodney’s experience in shepherding companies through the early stages of market introduction.”
Dr. Andreas Schmidt stated: “I have been fortunate to see AYOXXA grow from an idea I helped realize in the laboratory to a well-established company on the brink of commercial success.”
AYOXXA Biosystems GmbH is an international biotech company based in Cologne (Germany) with offices in Boston (USA) and Singapore. LUNARIS™ is AYOXXA’s innovative, patented beads-on-a-chip technology platform to analyze picogram amounts of multiple biomarkers in biological samples.
It delivers a high-quality immune-assay for sample volumes down to single-digit microliter, greatly expanding the types and number of samples from which scientists can gain insights. AYOXXA opens protein multiplexing opportunities to biomedicine, all the way from basic research to clinic and translational discoveries covering ophthalmology, mouse-to-man and immuno-oncology applications.
AYOXXA commercializes a portfolio of ready-to-use biomarker detection kits, e.g. LUNARIS™ Human & Mouse 5 to 12-Plex Cytokine Kits. With the introduction of AYOXXA Reader AR01, the company now offers a fully integrated solution for LUNARIS™ multiprotein analysis.
comments powered by